Format

Send to

Choose Destination
Transplantation. 2010 Jul 27;90(2):124-6. doi: 10.1097/TP.0b013e3181ea4240.

Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT).

Author information

1
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. m.hoogduijn@erasmusmc.nl

Abstract

There is evolving interest in the use of mesenchymal stem cells (MSC) in solid organ transplantation. Pre-clinical transplantation models show efficacy of MSC in prolonging graft survival and a number of clinical studies are planned or underway. At a recent meeting of the MISOT consortium (MSC In Solid Organ Transplantation) the advances of these studies were evaluated and mechanisms underlying the potential effects of MSC discussed. Continued discussion is required for definition of safety and eventually efficacy endpoints for MSC therapy in solid organ transplantation.

PMID:
20606604
DOI:
10.1097/TP.0b013e3181ea4240
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center